Introduction outcome is currently mainly deterWith improved treatments for acute rejection episodes, intestinal transplantation has evolved over the last decade from a cumbersome procedure with unacceptably high morbidity and mortality to a more acceptable therapy for patients with permanent intestinal failure. Altions, it is also hampered by chronic rejection [l, 191, which is the leading cause of late graft loss of other organs, such as the heart and kidney [4, 231. Indeed, some patients have lost their small bowel transplant due to chronic rejection [9, 23] .
~ ~
In contrast to our knowledge of the nature of the immune response and production of cytokines during acute intestinal rejection [31] , little is known about the involvement of cytokines in the pathophysiology of chronic rejection of intestinal transplants. The Pittsburgh group has given some attention to this issue. They demonstrated an increased expression of the cytokines IL-4 and interferon-y in chronically rejecting intestinal allografts, mainly localized in the thickened muscularis externa [30, 331. To further understand the mechanisms of tissue remodelling during chronic rejection of the small bowel, we have recently developed a rat model [3] . Histomorphological analysis has demonstrated mesenteric inflammation with sclerosis, myointima1 proliferation of mesenteric vessels, thickening of the muscularis, crypt hyperplasia, blunting of villi, and loss of goblet cells, features that have been found both in humans and in other animal models [6, 16, 191 . Some of these characteristics are consistent with the possible involvement of fibrogenic growth factors such as basic fibroblast growth factor (bFGF) and have been observed in other organs [12, 18] .
bFGF, or fibroblast growth factor-2 (FGF-2), a rnember of the FGF family, is a 133 to 154 amino acid (17.5 kDa) peptide that is mitogenic for vascular endothelial cells, smooth muscle cells, fibroblasts, and neural cells and chemotactic for macrophages and endothelial cells. It has been involved in wound healing and tissue regeneration [S] . bFGF has a high affinity for heparin and heparan sulphate proteoglycans, and it can thus be found in the extracellular matrix or bound to basement membranes [7] . The binding of bFGF to heparan sulphate proteoglycans protects it from inactivation by endogenous proteolytic agents.
In the digestive tract, bFGF peptide has been detected in duodenum [lS] and in normal gastric and colonic mucosa. It has been immunohistochemically localized to vessels, fibroblasts, and macrophages, with epithelial cells and extracellular matrix demonstrating no bFGF immunoreactivity [21] . Heparan sulphate proteoglycans act as the low-affinity receptors for bFGF in the intestine [17] , forming an FGF-heparin complex that facilitates the interaction between FGFs and their high-affinity cell surface tyrosine kinase receptors. The latter have been identified on various cell types, including smooth muscle cells, endothelial cells, macrophages, and intestinal epithelial cells [ 11, 141. The function of bFGF in the small intestine is not well defined. bFGF failed to promote epithelial restitution after colonic rnucosal damage in vitro [24] . Production of bFGF in the adult ileum has not yet been described. However, bFGF is known to be produced by activated macrophages, smooth muscle cells, and fibroblasts [8, 111 , and just these sources of bFGF could be important in the tissue remodelling processes of chronic intestinal rejection.
The aim of the present study was to evaluate the possible involvement of bFGF in the pathophysiology of chronic intestinal allograft rejection by analyzing gene and protein expression and distribution in the course of chronic rejection. 
Materials and methods

Groups
Chronic rejection model
The model of chronic rejection after small bowel transplantation has been described previously [3] . In brief, male, aduit inbred Dark-Agoud (DA)(RT-1"') and Albino-Surgery (AS)(RT-1') rats, obtained from Monash Animal Services, were used. Onestep orthotopic total small bowel transplantation was performed, as described previously [16] , in the allogeneic DA-to-AS rat combination. Cyclosporin, 5 mgikg per day was administered from day -2 until day 9 to prevent acute rejection. Rats were sacrificed at 50 days ( n = 6) or 100 days ( n = 5 ) post-transplantation. Small bowel grafts were removed and processed for histopathology, immunohistochemistry, and reverse transcriptase polymerase chain reaction (RT-PCR).
Isogra fts
Untreated DA isografts were included to control for nonallogeneic injury. Rats were sacrificed and grafts were removed at 50days ( n = 6) or 100 days ( n = 5 ) post-transplantation.
Normal rat small bowrl(DA)
Four small bowels from age-matched, normal DA rats were used as controls.
Processing of grafts
Small bowel grafts were retrieved under ether anesthesia, and rats were sacrificed immediately thereafkr. Portions of the ileum measuring approximately l cm were fixed in 10% buffered foi-malin and embedded in paraffin for histopathological studies and either snap-frozen in Tissue-Tek" (0. C.T. compound) (OCT) for immunohistochemistry or placed directly in liquid nitrogen for RNA extraction.
Histopathology
Paraffin sections, stained with hernatoxylin and eosin, were assessed in a blinded manner by two observers. The incidence of the following features was recorded for each of nine high-power fields (400 , = ): (a) blunting of villi and gohlet cell loss: (b) crypt hyper-plasia and necrosis: (c) thickening of the muscularis; and (d) inflammatory cell infiltration, vascular damage, and sclerosis of the mesentery. Scores of 0, 1,2, or 3 were assigned to features not observed or observed in 1/3,2/3, or all fields, respectively. Results obtained for each feature were added up, and added scores of 0 were classified as no damage, 1-3 as very mild (grade 1 ), 4-6 mild (grade 2), 7-9 moderate (grade 3), and 10-12 severe (grade 4).
Immunohistochemistry himunoreactive bFGF was assessed on 4-pm cryostat sections postfixed in periodate lysine paraformaldehyde (PLP) by a four-layer immunoperoxidase technique. Briefly, nonspecific binding was blocked by preincubation with 10% normal rabbit serum (Dako, Christchurch, New Zealand) in phosphate-buffered saline (PBS) with 0.01 YO sodium azide at room temperature. This was followed by overnight incubation with the primary mouse anti-bFGF (Upstate Biotechnology) and cell surface marker ED-? (a gift from Dr. C. D. Dijkstra, Amsterdam, The Netherlands). After each incubation. slides were washed in PBS-0.2 % gelatin. A second layer, goat anti-mouse IgG (Sigma, Castle Hill, Australia), was then applied for 30 min. Endogenous peroxidase activity was blocked by incubation for 10 min in methanol/0.3 % HzO,, after dehydration through graded alcohol. After rehydration and washing, the third and fourth layers -rabbit-anti goat immunoglobulin (Dako) and goat peroxidase anti-peroxidase (Dako)-were each applied for 30 min. The reaction was developed by the addition of metal-enhanced diaminobenzidine substrate (Pierce), and slides were counterstained in Harris hematoxylin. dehydrated, cleared, and mounted. Negative controls included sections in which the primary antibody was omitted for every animal. Isotype-specific control monoclonal antibodies (Dako) were also used. No staining was observed with these irrelevant antibodies.
The specificity of the antibodies to bFGF was confirmed by a solid phase absorption study, as previously described "91.
The immunohistochemical staining was analyzed by two observers, blind with regard to treatment group and time post-transplantation. Positive cells were counted in four different compartments of the ileum -villi, crypts, submucosa, and muscularisand were expressed as numbers of positive cells per 0.1 mm'.
Semiquantative reverse transcriptase polymerase chain reaction
R N A preparation
Total RNA was extracted from approximately 100 mg of snap-frozen, full-thickness ileum using the RNAzolImB method (Tel-test, Friendswood, Calif., USA). RNA was quantified spectrophotometrically and samples were diluted to 2.5 pg/pI.
c D N A synfhrsis
Reverse transcription reactions were set up using 1 yl of RNA (2.5 pg) in 20-~t1 volumes using an MULV RT system (Perkin Elmer, Foster City, Calif., USA).
PCR D N A urnplificution
PCR reactions were performed using a PCR amplification kit with AmpliTaq gold (Perkin Elmer). The co-amplification reaction for bFGF and glyceraldchyde-3-phosphate-dehydrogenase (GAP-DH) genes was optimized to ensure that the amplification of both genes was within the exponential phase at the end point of the PCR. Different concentrations of the primer pairs and of the Amplitaq gold were tested. Based on optimization experiments, PCR amplification reactions were performed in 25-pl volumes and contained 1.5 mM MgCIZ, x 1 PCR buffer, 1.25 U AmpliTaq gold, 100nM bFGF, 100nM GAPDH, and 2 . 5~1 cDNA. The following primers were used: bFGF sense: fluorescein (FI)-TCACTTCGCTTCCCGCACTG (519), antisense CCAGCAGC-CGTCCATCTT (787); GAPDH sense: FI-CCTTCATTGACC-TCAACTACATG (131). antisense: GATGACCTTGCCCAC-AGCCTT (667). The position of the 5 nucleotide of each primer in the published sequences [28, 32] is included within parentheses. Following an activating step for 12 min at 9 4 T , 35 cycles were performed with a denaturation step of 1 min at 9 4 T , an annealing temperature for I min and 30 sec starting at 72°C and decreasing by 0.4"C per cycle until 64"C, and an extension step of 2 min at 77 "C. The resulting PCR products had a length of 238 and 536 bp for bFGF and GAPDH respectively. The GAPDH primers were designed by Dr. P. Aldred and kindly provided by Dr. N. Cranswick. No interference was demonstrated between primer pairs.
Analysis of PCR products
The sense primers were labelled with fluorescein at the 5' end for direct detection of the PCR product bands using a laser-based fluorescence DNA detection system ( Fluorimager 575-Molecular Dynamics, Sunnyvale, Calif., USA). The volume of the individual bands was integrated using ImageQuant software (Molecular Dynamics), and ratios between bFGF and GAPDH bands were calculated. Four normal D A ileum samples were amplified and run with each group containing all isografts or allografts at day 50 or day 100 to enable comparisons between each group of amplified samples. Results obtained with normal DAwere standardized to 1. All samples were amplified and run in duplicate.
Statistical analysis
All statistical analyses were performed using SPSS for Windows. A Kruskal-Wallis nonparametric ANOVA was done, followed by Manu-Whitney U-test and Spearman correlations. The results are expressed as mean & SEM. A P value below 0.05 was accepted as significant.
Results
Histology
All allogeneic transplants developed chronic rejection (CR), although the severity of damage varied among animals from very mild to moderate. At 50 days, four out of six animals had moderate CR (grade 3). A progression of chronic damage with time was not evident. At 100 days post-transplantation, two of five rats had moderate changes. All other grafts had mild changes. Syngeneic grafts retained a normal architecture. 
Immunohistology
Normal itellrrl (Figs. 1 a,,31 The highest density of bFGF protein-expressing cells was located in the submucosa; a few positive cells were detected in the lamina propria of the villi and crypts, whereas epithelial cells were negative. bFGF-positive cells were present throughout the muscularis, their density being highest between the circular and longitudinal layers. Vessels did not show bFGF reactivity. isografisC allografts
-------I
Intestinal isografts
The number and distribution of bFGF protein-expressing cells did not differ from those of normal controls at either day 50 or day 100 (Fig. 2) .
Intestinal allografts (Figs. 1 c, 2)
The number of bFGF protein-expressing cells in allografts was approximately double that of isografts and normal D A Cp < 0.05 and p < 0.01, respectively) at 50 and 100 days. Immunohistochemical staining of normal D A ileum with ED-2 antibody demonstrated that the highest number of ED-2-positive cells was present in the submucosa. Very few tissue macrophages were present in the villi. The density was somewhat higher in the crypts. There lation at the border between the circular and longitudinal layer. Isografts did show a progressive increase in tissue macrophages over time; this attained significance at 100 days post-transplantation when compared to normal controls @ < 0.05; Fig. 2 ). This increase was found in all compartments, although it did not reach statistical significance in the crypts. Fifty days after transplantation, allografts demonstrated significantly more ED-2-positive macrophages than did isografts and normal D A ileum (p < 0.01). Increased numbers of macrophages were evident in villi, crypts, submucosa, and muscularis, with the highest density found in the submucosa. One hundred days after engraftment, the number of ED-2-positive macrophages in allografts was still significantly higher than in isografts and normal ileum 0, < 0.01 and p < 0.02, respectively) but did not differ significantly from day 50. The same pattern of distribution was observed.
The association between bFGF expression and tissue macrophages was further examined by performing a correlation study between bFGF-protein expressing cells and ED-2-positive macrophages. Taking all compartments together, bFGF protein expression was found to be significantly correlated with the number of tissue macrophages ( R = 0.86, p < 0.001, n = 25; Fig. 3) .
Furthermore, the number of bFGF protein-expressing cells was significantly correlated with the severity of chronic rejection ( R = 0.80, p < 0.001, n = 21; Fig. 4 ).
RT-PCR
The bFGF gene was transcriptionally active in normal DA ileum (Fig. 5) . Allografts demonstrated a significant increase in bFCF mRNA levels at 50 and 100 days postwere some positive cells in the muscularis, with accumu- 131. Chronic rejection of transplanted organs is characterized by an inflammatory infiltrate, graft arteriosclerosis, and fibrosis. Small bowel-specific features include thickening of the muscularis externa, crypt hyperplasia, and blunting of villi [3, 16, 191 . Because of its effects on smooth muscle cells, fibroblasts, and the extracellular matrix, bFGF would appear to be involved in the tissue remodelling of chronic rejection in intestinal transplants, as demonstrated in other organs [12, 181 . Moreover, bFGF has been found to act as a chemoattractant for macrophages [20] , a cell type that has repeatedly been observed in chronically rejected organs.
The present study showed the bFGF gene to be transcriptionally active in the ileum. This is the first time that bFGF mRNA has been detected in the adult intestine. Chowdhury et al. could not detect any signal in normal colorectal mucosa using RT-PCR [5]. Shimasaki et al. found that bFGF measured by Northern blot analysis could not be detected in the small intestine [28] . Our use of the full thickness of the intestine, combined with a sensitive KT-PCK protocol, may explain these differences. The bFGF protein was also present in normal and rejecting ileum.
The main finding of this study was a significant increase in bFGF mKNA and protein in chronic intestinal allograft rejection. This enhanced bFGF expression appeared to be correlated with the histological damage of the intestinal grafts, further suggesting a role for this growth factor in the tissue remodelling. In contrast, chronic vascular rejection in lung allografts did not coincide with bFGF immunoreactivity; bFGF was only markedly upregulated in the early phase and restricted to peribronchiolar and perivascular infiltrates [18] . Nor did bFGF correlate with the degree of transplant vasculopathy in bioptied heart allografts [27, 341 or in aorta allografts [22] . Indeed, myoproliferation of the intra-intestinal arteries was not accompanied by enhanced bFGF immunoreactivity. Therefore, bFGF appears to be important in organ-specific remodelling, i. e., in muscular thickening and neuron repair, rather than being involved in transplant arteriosclerosis.
Many of the bFGF-expressing cells appeared to be ED-2-positive macrophages. Furthermore, the number of bFGF protein and ED-2-positive cells was significantly correlated, strongly suggesting that the macrophage is an important source of bFGF. Lee et al. also found that bFGF protein was mainly expressed by infiltrating cells, including macrophages, in lung allografts [18] . The production of bFGF by macrophages has been unequivocally demonstrated by PCK and Northern blot analysis of macrophage mRNA 1113.
bFGF-expressing cells and tissue macrophages in allografts were mainly localized in the submucosa and the muscularis, particularly between the longitudinal and circular layers. Since the neural plexus are localized in these areas, bFGF and macrophages may not only be associated with muscular thickening, but may also act in the intrinsic neural plexus. Lee et al. found a suppressed neuromuscular transmission during subclinical chronic intestinal rejection that is related to the loss of enteric neurons as a consequence of extrinsic denervation [lo] . Since bFGF is known to stimulate neuron outgrowth [8] , the preferential site of bFGF-expressing cells could reflect an attempt to repair the intrinsic neural plexus.
We did not detect bFGF protein immunohistochemically in epithelial cells of normal intestine, which is consistent with the results of Ohtani et al. [21] . Moreover, no staining was seen in the damaged mucosa of chronically rejecting intestinal allografts, suggesting that endogenous bFGF is not involved in the repair of epithelial damage in CR.
Although the influx of macrophages into isografts was significantly higher than in normal ileum, histologically the intestinal grafts were well preserved during follow-up. Also, bFGF protein and mKNA remained at the nontransplanted level, further suggesting that the macrophages in the isografts were inactive.
Based on the present data, we postulate that bFGF may have important effects that contribute to CR of intestinal grafts. bFGF is a chemoattractant for macrophages, contributing to the persistent increase in macrophages in chronic intestinal rejection. Activated macrophages, in turn, produce bFGF and other fibrogenic cytokines, including TGF-beta and PDGF, and have been shown to play a pivotal role in the process of CK [2, 2.51. bFGF also has a mitogenic effect on smooth muscle cells, enhancing the hypertrophy of the muscularis. The localization of bFGF also suggests that it may have a positive effect on neuron outgrowth.
To further understand the contribution of bFGF to CR and its relationship with tissue macrophages, studies on the effect of neutralization of bFGF protein and on the effect of a selective inhibition of macrophages should be performed.
